Who We Are
Innovating Regenerative Medicine
From Academic Innovation to Transformative Therapeutics
Academic Origin
Spun out from The Chinese University of Hong Kong (CUHK) in 2023
Therapeutic Focus
Developing first-in-class cytokine-based therapies for vascular diseases
Expert Team
Over 40% R&D scientists with translational and commercial expertise
Ecosystem Support
Accelerated by CUHK and HKSTP programs, funded by Hong Kong ITF
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
Our Mission
AI & Regenerative Medicine
Key Milestones & Metrics
Progress in Action
10
1
1
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION
-
TOTAL VASCULAR SOLUTION